Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS mutations in non-small cell lung cancer.

Proceedings of the American Thoracic Society - 15 Apr 2009

Riely Gregory J, Marks Jenifer, Pao William

Abstract excerpt

Some non-small cell lung cancers (NSCLCs) harbor a single specific mutated oncogene that is thought to be the primary genetic "driver" leading to cancer. The two most commonly mutated oncogenes in lung cancer encode for the epidermal growth factor receptor (EGFR) and KRAS. EGFR kinase domain mutations were only recently identified, but they have already been established in the clinic as valid predictors of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to Lung Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Risk Factors

Source

Identifiers

PMID: 19349489
DOI: 10.1513/pats.200809-107LC

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS mutations in non-small cell lung cancer.PMID 19349489Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation.Semantic proximity Read ↗

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.Semantic proximity Read ↗

KRAS mutations as prognostic and predictive markers in non-small cell lung cancer.Semantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

KRAS mutation: should we test for it, and does it matter?Semantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

KRAS mutant lung cancer: progress thus far on an elusive therapeutic targetSemantic proximity Read ↗

The genetics and biology of KRAS in lung cancer.Semantic proximity Read ↗

KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.